<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">11223855</article-id>
    <article-id pub-id-type="pmid">38682594</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkae304</article-id>
    <article-id pub-id-type="publisher-id">gkae304</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00010</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Web Server Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>SynDesign: web-based prime editing guide RNA design and evaluation tool for saturation genome editing</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Park</surname>
          <given-names>Jinman</given-names>
        </name>
        <aff><institution>Department of Pharmacology, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Graduate School of Medical Science, Brain Korea 21 Plus Project for Medical Sciences, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yu</surname>
          <given-names>Goosang</given-names>
        </name>
        <aff><institution>Department of Pharmacology, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Graduate School of Medical Science, Brain Korea 21 Plus Project for Medical Sciences, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Seo</surname>
          <given-names>Sang-Yeon</given-names>
        </name>
        <aff><institution>Department of Pharmacology, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Graduate School of Medical Science, Brain Korea 21 Plus Project for Medical Sciences, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yang</surname>
          <given-names>Jinyeong</given-names>
        </name>
        <aff><institution>Department of Pharmacology, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Graduate School of Medical Science, Brain Korea 21 Plus Project for Medical Sciences, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4693-738X</contrib-id>
        <name>
          <surname>Kim</surname>
          <given-names>Hyongbum Henry</given-names>
        </name>
        <!--hkim1@yuhs.ac-->
        <aff><institution>Department of Pharmacology, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Graduate School of Medical Science, Brain Korea 21 Plus Project for Medical Sciences, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Severance Biomedical Science Institute, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Center for Nanomedicine, Institute for Basic Science (IBS)</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Yonsei-IBS Institute, Yonsei University</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Woo Choo Lee Institute for Precision Drug Development, Yonsei University College of Medicine</institution>, Seoul 03722, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Won-Sang Lee Institute for Hearing Loss, Yonsei University College of Medicine</institution>, Seoul 03722, <country country="KR">Republic of Korea</country></aff>
        <xref rid="COR1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +82 2 2228 0879; Fax: +82 2 313 1894; Email: <email>hkim1@yuhs.ac</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <day>05</day>
      <month>7</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2024-04-29">
      <day>29</day>
      <month>4</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>29</day>
      <month>4</month>
      <year>2024</year>
    </pub-date>
    <volume>52</volume>
    <issue>W1</issue>
    <fpage>W121</fpage>
    <lpage>W125</lpage>
    <history>
      <date date-type="accepted">
        <day>24</day>
        <month>4</month>
        <year>2024</year>
      </date>
      <date date-type="rev-recd">
        <day>22</day>
        <month>3</month>
        <year>2024</year>
      </date>
      <date date-type="received">
        <day>04</day>
        <month>2</month>
        <year>2024</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2024. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2024</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkae304.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Saturation genome editing (SGE) enables in-depth functional evaluation of disease-associated genes and variants by generating all possible single nucleotide variants (SNVs) within a given coding region. Although prime editing can be employed for inducing these SNVs, designing efficient prime editing guide RNAs (pegRNAs) can be challenging and time-consuming. Here, we present SynDesign, an easy-to-use webtool for the design, evaluation, and construction precision pegRNA libraries for SGE with synonymous mutation markers. SynDesign offers a simple yet powerful interface that automates the generation of all feasible pegRNA designs for a target gene or variant of interest. The pegRNAs are selected using the state-of-the-art models to predict prime editing efficiencies for various prime editors and cell types. Top-scoring pegRNA designs are further enhanced using synonymous mutation markers which improve pegRNA efficiency by diffusing the cellular mismatch repair mechanism and serve as sequence markers for improved identification of intended edits following deep sequencing. SynDesign is expected to facilitate future research using SGE to investigate genes or variants of interest associated with human diseases. SynDesign is freely available at <ext-link xlink:href="https://deepcrispr.info/SynDesign" ext-link-type="uri">https://deepcrispr.info/SynDesign</ext-link> without a login process.</p>
    </abstract>
    <abstract abstract-type="graphical">
      <title>Graphical Abstract</title>
      <p>
        <fig position="float" id="ga1">
          <label>Graphical Abstract</label>
          <graphic xlink:href="gkae304figgra1" position="float"/>
        </fig>
      </p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Research Foundation of Korea</institution>
            <institution-id institution-id-type="DOI">10.13039/501100003725</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Korean government</institution>
          </institution-wrap>
        </funding-source>
        <award-id>2022R1A3B1078084</award-id>
        <award-id>2018R1A5A2025079</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Bio and Medical Technology Development Program of the NRF</institution>
          </institution-wrap>
        </funding-source>
        <award-id>2022M3A9E4017127</award-id>
        <award-id>2022M3A9F3017506</award-id>
        <award-id>RS-2023-00260968</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Yonsei Signature Research Cluster Program of 2023-22- 0012</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Brain Korea 21 FOUR Project for Medical Science</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>SNUH Kun-hee Lee Child Cancer and Rare Disease Project, Republic of Korea</institution>
          </institution-wrap>
        </funding-source>
        <award-id>22B-000-0101</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Lee Youn Jae</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="5"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>Introduction</title>
    <p>When first introduced, prime editing presented a novel and powerful utility to genome editing by introducing prime editing guide RNAs (pegRNAs) that could be designed to install all possible point mutations a well as small insertions and deletions (indels), or any combinations of these DNA alterations to a target DNA sequence (<xref rid="B1" ref-type="bibr">1</xref>). However, the design and evaluation of pegRNAs for efficient prime editing have been a challenge as various sequence and biochemical factors can attribute to efficient pegRNAs (<xref rid="B1" ref-type="bibr">1–3</xref>). Furthermore, cell conditions exhibiting differential levels of mismatch repair (MMR) systems can also play a role in determining editing efficiencies. Notably, introducing a synonymous mutation adjacent to the intended edit on the target DNA have been shown to improve on-target prime editing efficiency by diffusing the local cellular MMR activity (<xref rid="B3" ref-type="bibr">3</xref>). Additionally, the synonymous mutation can serve as an indicator of properly edited targets following deep sequencing (<xref rid="B4" ref-type="bibr">4</xref>). Taken together, the application of prime editing for saturation genome editing (SGE) can be a powerful tool in conducting systematic functional screening of variants for target genes of interest, especially for investigating variants of uncertain significance (VUS) that represent a major portion of the single nucleotide variants (SNVs) on the ClinVar and COSMIC databases, 95% and 99%, respectively (Figure <xref rid="F1" ref-type="fig">1</xref>). However, the designing and evaluation efficient pegRNAs for generating SNVs at every nucleotide position within a given coding sequence of a target gene present technical challenges that may hinder its wider application in research. Despite recent computational models based on deep learning greatly aiding our understanding of pegRNA designs and facilitating prime editing applications in diverse cell types and PEs (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>), reliable and easy-to-use tools for SGE library design and evaluation have been limited.</p>
    <fig position="float" id="F1">
      <label>Figure 1.</label>
      <caption>
        <p>Distribution of VUSs in ClinVar and COSMIC databases. Of the variants categorized as uncertain significance or unknow origin, ClinVar and COSMIC databases respectively (VUS or simplicity), a major portion of them are single nucleotide variants and easily targetable by SynDesign. Investigating these VUSs remains an important task for understanding their role in human disease.</p>
      </caption>
      <graphic xlink:href="gkae304fig1" position="float"/>
    </fig>
    <p>Here, we present SynDesign, a web-based platform developed for the systematic design and assessment of pegRNAs, specifically tailored for the construction of precision pegRNA libraries employed in SGE. SynDesign provides an efficient and user-friendly means to easily target genes or variants of interest, streamlining the automation of pegRNA design and evaluation processes. Moreover, it seamlessly incorporates synonymous mutation markers into pegRNA designs, generating a curated list of top-performing pegRNAs for experimental applications. SynDesign is expected to alleviate the labor-intensive procedures associated with pegRNA design and facilitate the widespread adoption of SGE across diverse research applications.</p>
  </sec>
  <sec sec-type="materials|methods" id="SEC2">
    <title>Materials and methods</title>
    <sec id="SEC2-1">
      <title>SynDesign webtool</title>
      <p>SynDesign was developed using Python 3.9.13 on CodeIgniter 5 based on PHP 5.2.4. The web interface was developed using Bootstrap 5 and made accessible using Apache 2.4.18.</p>
    </sec>
    <sec id="SEC2-2">
      <title>Input processing</title>
      <p>To facilitate the systematic targeting of genes or variants of interest, the major databases for obtaining reference gene information on the human genome and genetic variants were collected, cleaned and indexed for fast and resource-efficient manipulation. Databases included the NCBI’s RefSeq gene information (<xref rid="B7" ref-type="bibr">7</xref>), Ensembl database for vertebrate genomes (<xref rid="B8" ref-type="bibr">8</xref>), the HUGO Gene Nomenclature Committee, HGNC, database (<xref rid="B9" ref-type="bibr">9</xref>), where the gene name and symbol, with corresponding identification and accession numbers for representative gene forms were cross-referenced and verified using an in-house Python script. In doing so, a reliable reference list of &gt;18 000 human genes and their collective IDs from each database was established. In addition, we collected and indexed the latest version of ClinVar (<xref rid="B10" ref-type="bibr">10</xref>) and COSMIC (<xref rid="B11" ref-type="bibr">11</xref>) variant archives for quickly identifying variant ID queries and generating a library of pegRNAs targeting the variant location for installing or editing the mutation.</p>
    </sec>
    <sec id="SEC2-3">
      <title>PegRNA design and scoring</title>
      <p>Genic information for target genes including transcription start and end positions, the coding sequence (CDS) start and end positions, and the exon count are retrieved using the in-house reference gene list. Using these coordinates, the CDS sequences are fetched from genome version GRCh38/hg38. Within the given CDS sequence, all possible pegRNA designs are determined for each position in the CDS sequence to elicit all three SNV alterations. Components such as the reverse transcription template (RTT) (max 40 bp) and primer-binding site (PBS) (max 17 bp) sequences are determined according to DeepPrime input parameters. Variant inputs from the ClinVar and COSMIC archives or single position input require considerably less computational resources as only a single position is targeted.</p>
      <p>All pegRNAs are evaluated using DeepPrime and DeepPrime-FT and ranked according to predicted efficiency scores. DeepPrime and DeepPrime-FT are CNN + GRU-based deep learning model developed on pytorch 1.9.1 that predicts prime editing efficiencies for introducing 1–3-bp substitutions, insertions, or deletions at any given target sites in the human genome (<xref rid="B2" ref-type="bibr">2</xref>). It was developed and fine-tuned using more than 300 000 pegRNAs for a diverse group of prime editors and cell types and validated against multiple independent datasets from previous studies (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>).</p>
    </sec>
    <sec id="SEC2-4">
      <title>Output processing and visualization</title>
      <p>As co-editing of the PAM sequence has been shown to increase editing efficiency (<xref rid="B5" ref-type="bibr">5</xref>), the incorporation of a synonymous mutation marker is prioritized to the PAM sequence but can be user-specified to other region of the pegRNA design. Visualization of the results include important features of the top pegRNAs ranked according to the predicted efficiency scores included genic coordinates, nucleotide and amino acid changes, and <italic toggle="yes">Z</italic>-score graph of the top pegRNA designs against those from model testing for the corresponding PE and cell type (Figure <xref rid="F2" ref-type="fig">2</xref>). This contextual information provides a more complete understanding of their efficiency in relation to a more general performance of pegRNAs under similar experimental conditions.</p>
      <fig position="float" id="F2">
        <label>Figure 2.</label>
        <caption>
          <p>Sample Result Page from SynDesign. Interactive results page from <italic toggle="yes">TP53</italic> exon 5 run shows pertinent information regarding the pegRNAs ranked according to predicted efficiency scores from DeepPrime. The <italic toggle="yes">z</italic>-score plot depicts the score of the selected pegRNA compared to those from model training under the same prime editor and cellular conditions. Top 200 pegRNAs are shown as default but a link to download the full results is available at the bottom of the page.</p>
        </caption>
        <graphic xlink:href="gkae304fig2" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec sec-type="results" id="SEC3">
    <title>Results</title>
    <sec id="SEC3-1">
      <title>Analysis: gene target</title>
      <p>For GeneSym, NMID, Ensembl and HGNC, the target gene information is automatically filled within a dropdown menu that includes the corresponding target gene's gene symbol, chromosome number and strand, and the exon numbers that include the CDS for quick reference by the user. Exons can be targeted by the number with single exon being the best for current available resources. Recently, we used SynDesign to develop a saturation resistance profiling library of the <italic toggle="yes">EGFR</italic> gene against various the chemotherapy drugs, afatinib and osimertinib. A SGE library was designed and evaluated to profile over 2476 SNVs in the EGFR gene that included 95% (1726/1817) of the possible protein variants in the tyrosine kinase domain (exons 18–21) which represents an important functional hotspot for cancer-related mutations (<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B14" ref-type="bibr">14</xref>). SynDesign was able to compile a list of all feasible pegRNAs targeting every position in the <italic toggle="yes">EGFR</italic> gene to systematically evaluate this important oncogene. SynDesign determines the top pegRNAs for each position according to our DeepPrime/DeepPrime-FT prediction models and automatically incorporates a synonymous mutation marker that further enhances pegRNA efficiency and sequenced product identification.</p>
    </sec>
    <sec id="SEC3-2">
      <title>Analysis: variant targets</title>
      <p>For specific variant targets from ClinVar or COSMIC archives, the mutation ID from each database can be used without the lettering prefix fillers, VCV- and COSM-, respectively. The model or therapy setting switches the wild-type (unedited) and edited sequences in the input processing step to construct a library for disease modelling (installing the mutation) or disease therapy (correcting the mutation), respectively. There are more than 600K and 750K variants that are categorized as VUS on the ClinVar and COSMIC databases respectively. Of these VUSs, 95% and 99% are SNVs (Figure <xref rid="F1" ref-type="fig">1</xref>). SynDesign can quickly retrieve these VUSs to generate all possible pegRNA designs targeting the VUS and score each pegRNA using DeepPrime/DeepPrime-FT. This secondary function to SGE that retrieves target variants directly from the ClinVar and COSMIC archives can further enhance the systematic survey of VUSs associated with human disease such as cancers. SynDesign is expected to serve as a useful platform that can aid in addressing this critical need in the investigation of VUSs.</p>
    </sec>
    <sec id="SEC3-3">
      <title>Limitations of SynDesign</title>
      <p>The basic sequence and position inputs are intended for quick test runs as they do not involve gene annotation or additional annotation using the variant archives. The sequence input tests single unedited and edited sequences of 121-bp in length that follows the DeepPrime protocol, <ext-link xlink:href="https://deepcrispr.info/DeepPrime" ext-link-type="uri">https://deepcrispr.info/DeepPrime</ext-link>. The computational requirements for conducting full gene or multiple exon runs have proven to be prohibitive, surpassing reasonable runtimes and exceeding the VRAM limits of our existing webserver infrastructure.</p>
    </sec>
  </sec>
  <sec sec-type="discussion" id="SEC4">
    <title>Discussion</title>
    <p>This paper introduces a user-friendly platform designed for precision targeting of genes or variants of interest. The platform seamlessly integrates systematic pegRNA design with robust prediction models, DeepPrime and DeepPrime-FT. SynDesign generates results that include synonymous mutation markers and important features for the top predicted pegRNAs, facilitating precision SGE for target genes and constructing robust pegRNA libraries for variants of interest. Thorough documentation including all available parameters and sample inputs and expected interactive outcomes, are accessible through the Support section of the webpage.</p>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>Acknowledgements</title>
    <p>We would like to thank Younghye Kim and Seonmi Park for assisting with the experiments..</p>
  </ack>
  <sec sec-type="data-availability" id="SEC5">
    <title>Data availability</title>
    <p>SynDesign is freely available at <ext-link xlink:href="https://deepcrispr.info/SynDesign" ext-link-type="uri">https://deepcrispr.info/SynDesign</ext-link>. Webtool version of the custom Python code for guide design and feature extraction is available on <ext-link xlink:href="https://github.com/josephjinpark/SynDesign" ext-link-type="uri">https://github.com/josephjinpark/SynDesign</ext-link> and <ext-link xlink:href="https://doi.org/10.6084/m9.figshare.25565994" ext-link-type="uri">https://doi.org/10.6084/m9.figshare.25565994</ext-link>.</p>
  </sec>
  <sec id="SEC6">
    <title>Funding</title>
    <p>National Research Foundation of Korea grant funded by the Korean government (MSIT) [2022R1A3B1078084 to H.H.K., 2018R1A5A2025079 to H.H.K.]; Bio and Medical Technology Development Program of the NRF funded by the Korean government (MSIT) [2022M3A9E4017127 to H.H.K., 2022M3A9F3017506 to H.H.K., RS-2023-00260968 to H.H.K.]; Yonsei Signature Research Cluster Program of 2023-22- 0012 (to H.H.K.); Brain Korea 21 FOUR Project for Medical Science (Yonsei University College of Medicine); SNUH Kun-hee Lee Child Cancer and Rare Disease Project, Republic of Korea [22B-000-0101 to H.H.K.]; Yonsei Fellow Program, funded by Lee Youn Jae. Funding for open access charge: National Research Foundation of Korea grant funded by the Korean government (MSIT) [2022R1A3B1078084 to H.H.K., 2018R1A5A2025079 to H.H.K.]; Bio and Medical Technology Development Program of the NRF funded by the Korean government (MSIT) [2022M3A9E4017127 to H.H.K., 2022M3A9F3017506 to H.H.K., RS-2023-00260968 to H.H.K.]; Yonsei Signature Research Cluster Program of 2023-22- 0012 (to H.H.K.); Brain Korea 21 FOUR Project for Medical Science (Yonsei University College of Medicine); SNUH Kun-hee Lee Child Cancer and Rare Disease Project, Republic of Korea [22B-000-0101 to H.H.K.]; Yonsei Fellow Program, funded by Lee Youn Jae.</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. Authors declare no conflicts of interest.</p>
  </sec>
  <ref-list id="REF1">
    <title>References</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Anzalone</surname>  <given-names>A.V.</given-names></string-name>, <string-name><surname>Randolph</surname>  <given-names>P.B.</given-names></string-name>, <string-name><surname>Davis</surname>  <given-names>J.R.</given-names></string-name>, <string-name><surname>Sousa</surname>  <given-names>A.A.</given-names></string-name>, <string-name><surname>Koblan</surname>  <given-names>L.W.</given-names></string-name>, <string-name><surname>Levy</surname>  <given-names>J.M.</given-names></string-name>, <string-name><surname>Chen</surname>  <given-names>P.J.</given-names></string-name>, <string-name><surname>Wilson</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Newby</surname>  <given-names>G.A.</given-names></string-name>, <string-name><surname>Raguram</surname>  <given-names>A.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Search-and-replace genome editing without double-strand breaks or donor DNA</article-title>. <source>Nature</source>. <year>2019</year>; <volume>576</volume>:<fpage>149</fpage>–<lpage>157</lpage>.<pub-id pub-id-type="pmid">31634902</pub-id>
</mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yu</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>H.K.</given-names></string-name>, <string-name><surname>Park</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Kwak</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Cheong</surname>  <given-names>Y.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>D.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>H.H</given-names></string-name></person-group>  <article-title>Prediction of efficiencies for diverse prime editing systems in multiple cell types</article-title>. <source>Cell</source>. <year>2023</year>; <volume>186</volume>:<fpage>2256</fpage>–<lpage>2272</lpage>.<pub-id pub-id-type="pmid">37119812</pub-id>
</mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname>  <given-names>P.J.</given-names></string-name>, <string-name><surname>Hussmann</surname>  <given-names>J.A.</given-names></string-name>, <string-name><surname>Yan</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Knipping</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Ravisankar</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Chen</surname>  <given-names>P.F.</given-names></string-name>, <string-name><surname>Chen</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Nelson</surname>  <given-names>J.W.</given-names></string-name>, <string-name><surname>Newby</surname>  <given-names>G.A.</given-names></string-name>, <string-name><surname>Sahin</surname>  <given-names>M.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Enhanced prime editing systems by manipulating cellular determinants of editing outcomes</article-title>. <source>Cell</source>. <year>2021</year>; <volume>184</volume>:<fpage>5635</fpage>–<lpage>5652</lpage>.<pub-id pub-id-type="pmid">34653350</pub-id>
</mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Kim</surname>  <given-names>Y.</given-names></string-name>, <string-name><surname>Oh</surname>  <given-names>H.-C.</given-names></string-name>, <string-name><surname>Lee</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>H.H.</given-names></string-name></person-group>  <article-title>Saturation resistance profiling of EGFR variants against tyrosine kinase inhibitors using prime editing</article-title>. <year>2023</year>; <comment>bioRxiv doi:</comment><comment>05 December 2023, preprint: not peer reviewed</comment><pub-id pub-id-type="doi">10.1101/2023.12.03.569825</pub-id>.</mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname>  <given-names>H.K.</given-names></string-name>, <string-name><surname>Yu</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Park</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Min</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Lee</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Yoon</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>H.H.</given-names></string-name></person-group>  <article-title>Predicting the efficiency of prime editing guide RNAs in human cells</article-title>. <source>Nat. Biotechnol.</source>  <year>2021</year>; <volume>39</volume>:<fpage>198</fpage>–<lpage>206</lpage>.<pub-id pub-id-type="pmid">32958957</pub-id>
</mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mathis</surname>  <given-names>N.</given-names></string-name>, <string-name><surname>Allam</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Kissling</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Marquart</surname>  <given-names>K.F.</given-names></string-name>, <string-name><surname>Schmidheini</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Solari</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Balazs</surname>  <given-names>Z.</given-names></string-name>, <string-name><surname>Krauthammer</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Schwank</surname>  <given-names>G.</given-names></string-name></person-group>  <article-title>Predicting prime editing efficiency and product purity by deep learning</article-title>. <source>Nat. Biotechnol.</source>  <year>2023</year>; <volume>41</volume>:<fpage>1151</fpage>–<lpage>1159</lpage>.<pub-id pub-id-type="pmid">36646933</pub-id>
</mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>O’Leary</surname>  <given-names>N.A.</given-names></string-name>, <string-name><surname>Wright</surname>  <given-names>M.W.</given-names></string-name>, <string-name><surname>Brister</surname>  <given-names>J.R.</given-names></string-name>, <string-name><surname>Ciufo</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Haddad</surname>  <given-names>D.</given-names></string-name>, <string-name><surname>McVeigh</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Rajput</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Robbertse</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Smith-White</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Ako-Adjei</surname>  <given-names>D.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation</article-title>. <source>Nucleic Acids Res.</source>  <year>2016</year>; <volume>44</volume>:<fpage>D733</fpage>–<lpage>D745</lpage>.<pub-id pub-id-type="pmid">26553804</pub-id>
</mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Harrison</surname>  <given-names>P.W.</given-names></string-name>, <string-name><surname>Amode</surname>  <given-names>M.R.</given-names></string-name>, <string-name><surname>Austine-Orimoloye</surname>  <given-names>O.</given-names></string-name>, <string-name><surname>Azov</surname>  <given-names>A.G.</given-names></string-name>, <string-name><surname>Barba</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Barnes</surname>  <given-names>I.</given-names></string-name>, <string-name><surname>Becker</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Bennett</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Berry</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Bhai</surname>  <given-names>J.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Ensembl 2024</article-title>. <source>Nucleic Acids Res.</source>  <year>2024</year>; <volume>52</volume>:<fpage>D891</fpage>–<lpage>D899</lpage>.<pub-id pub-id-type="pmid">37953337</pub-id>
</mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Seal</surname>  <given-names>R.L.</given-names></string-name>, <string-name><surname>Braschi</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Gray</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Jones</surname>  <given-names>T.E.M.</given-names></string-name>, <string-name><surname>Tweedie</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Haim-Vilmovsky</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Bruford</surname>  <given-names>E.A.</given-names></string-name></person-group>  <article-title>Genenames.org: the HGNC resources in 2023</article-title>. <source>Nucleic Acids Res.</source>  <year>2023</year>; <volume>51</volume>:<fpage>D1003</fpage>–<lpage>D1009</lpage>.<pub-id pub-id-type="pmid">36243972</pub-id>
</mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Landrum</surname>  <given-names>M.J.</given-names></string-name>, <string-name><surname>Lee</surname>  <given-names>J.M.</given-names></string-name>, <string-name><surname>Benson</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Brown</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Chao</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Chitipiralla</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Gu</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Hart</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Hoffman</surname>  <given-names>D.</given-names></string-name>, <string-name><surname>Hoover</surname>  <given-names>J.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>ClinVar: public archive of interpretations of clinically relevant variants</article-title>. <source>Nucleic Acids Res.</source>  <year>2016</year>; <volume>44</volume>:<fpage>D862</fpage>–<lpage>D868</lpage>.<pub-id pub-id-type="pmid">26582918</pub-id>
</mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sondka</surname>  <given-names>Z.</given-names></string-name>, <string-name><surname>Dhir</surname>  <given-names>N.B.</given-names></string-name>, <string-name><surname>Carvalho-Silva</surname>  <given-names>D.</given-names></string-name>, <string-name><surname>Jupe</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Madhumita</surname></string-name>, <string-name><surname>McLaren</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Starkey</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Ward</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Wilding</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Ahmed</surname>  <given-names>M.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>COSMIC: a curated database of somatic variants and clinical data for cancer</article-title>. <source>Nucleic Acids Res.</source>  <year>2024</year>; <volume>52</volume>:<fpage>D1210</fpage>–<lpage>D1217</lpage>.<pub-id pub-id-type="pmid">38183204</pub-id>
</mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jang</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Jo</surname>  <given-names>D.H.</given-names></string-name>, <string-name><surname>Cho</surname>  <given-names>C.S.</given-names></string-name>, <string-name><surname>Shin</surname>  <given-names>J.H.</given-names></string-name>, <string-name><surname>Seo</surname>  <given-names>J.H.</given-names></string-name>, <string-name><surname>Yu</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Gopalappa</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>D.</given-names></string-name>, <string-name><surname>Cho</surname>  <given-names>S.R.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>J.H.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases</article-title>. <source>Nat. Biomed. Eng.</source>  <year>2022</year>; <volume>6</volume>:<fpage>181</fpage>–<lpage>194</lpage>.<pub-id pub-id-type="pmid">34446856</pub-id>
</mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Erwood</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Bily</surname>  <given-names>T.M.I.</given-names></string-name>, <string-name><surname>Lequyer</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Yan</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Gulati</surname>  <given-names>N.</given-names></string-name>, <string-name><surname>Brewer</surname>  <given-names>R.A.</given-names></string-name>, <string-name><surname>Zhou</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Pelletier</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Ivakine</surname>  <given-names>E.A.</given-names></string-name>, <string-name><surname>Cohn</surname>  <given-names>R.D.</given-names></string-name></person-group>  <article-title>Saturation variant interpretation using CRISPR prime editing</article-title>. <source>Nat. Biotechnol.</source>  <year>2022</year>; <volume>40</volume>:<fpage>885</fpage>–<lpage>895</lpage>.<pub-id pub-id-type="pmid">35190686</pub-id>
</mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sharma</surname>  <given-names>S.V.</given-names></string-name>, <string-name><surname>Bell</surname>  <given-names>D.W.</given-names></string-name>, <string-name><surname>Settleman</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Haber</surname>  <given-names>D.A.</given-names></string-name></person-group>  <article-title>Epidermal growth factor receptor mutations in lung cancer</article-title>. <source>Nat. Rev. Cancer</source>. <year>2007</year>; <volume>7</volume>:<fpage>169</fpage>–<lpage>181</lpage>.<pub-id pub-id-type="pmid">17318210</pub-id>
</mixed-citation>
    </ref>
  </ref-list>
</back>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">11223855</article-id>
    <article-id pub-id-type="pmid">38682594</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkae304</article-id>
    <article-id pub-id-type="publisher-id">gkae304</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00010</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Web Server Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>SynDesign: web-based prime editing guide RNA design and evaluation tool for saturation genome editing</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Park</surname>
          <given-names>Jinman</given-names>
        </name>
        <aff><institution>Department of Pharmacology, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Graduate School of Medical Science, Brain Korea 21 Plus Project for Medical Sciences, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yu</surname>
          <given-names>Goosang</given-names>
        </name>
        <aff><institution>Department of Pharmacology, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Graduate School of Medical Science, Brain Korea 21 Plus Project for Medical Sciences, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Seo</surname>
          <given-names>Sang-Yeon</given-names>
        </name>
        <aff><institution>Department of Pharmacology, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Graduate School of Medical Science, Brain Korea 21 Plus Project for Medical Sciences, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yang</surname>
          <given-names>Jinyeong</given-names>
        </name>
        <aff><institution>Department of Pharmacology, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Graduate School of Medical Science, Brain Korea 21 Plus Project for Medical Sciences, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4693-738X</contrib-id>
        <name>
          <surname>Kim</surname>
          <given-names>Hyongbum Henry</given-names>
        </name>
        <!--hkim1@yuhs.ac-->
        <aff><institution>Department of Pharmacology, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Graduate School of Medical Science, Brain Korea 21 Plus Project for Medical Sciences, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Severance Biomedical Science Institute, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Center for Nanomedicine, Institute for Basic Science (IBS)</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Yonsei-IBS Institute, Yonsei University</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Woo Choo Lee Institute for Precision Drug Development, Yonsei University College of Medicine</institution>, Seoul 03722, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Won-Sang Lee Institute for Hearing Loss, Yonsei University College of Medicine</institution>, Seoul 03722, <country country="KR">Republic of Korea</country></aff>
        <xref rid="COR1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +82 2 2228 0879; Fax: +82 2 313 1894; Email: <email>hkim1@yuhs.ac</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <day>05</day>
      <month>7</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2024-04-29">
      <day>29</day>
      <month>4</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>29</day>
      <month>4</month>
      <year>2024</year>
    </pub-date>
    <volume>52</volume>
    <issue>W1</issue>
    <fpage>W121</fpage>
    <lpage>W125</lpage>
    <history>
      <date date-type="accepted">
        <day>24</day>
        <month>4</month>
        <year>2024</year>
      </date>
      <date date-type="rev-recd">
        <day>22</day>
        <month>3</month>
        <year>2024</year>
      </date>
      <date date-type="received">
        <day>04</day>
        <month>2</month>
        <year>2024</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2024. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2024</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkae304.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Saturation genome editing (SGE) enables in-depth functional evaluation of disease-associated genes and variants by generating all possible single nucleotide variants (SNVs) within a given coding region. Although prime editing can be employed for inducing these SNVs, designing efficient prime editing guide RNAs (pegRNAs) can be challenging and time-consuming. Here, we present SynDesign, an easy-to-use webtool for the design, evaluation, and construction precision pegRNA libraries for SGE with synonymous mutation markers. SynDesign offers a simple yet powerful interface that automates the generation of all feasible pegRNA designs for a target gene or variant of interest. The pegRNAs are selected using the state-of-the-art models to predict prime editing efficiencies for various prime editors and cell types. Top-scoring pegRNA designs are further enhanced using synonymous mutation markers which improve pegRNA efficiency by diffusing the cellular mismatch repair mechanism and serve as sequence markers for improved identification of intended edits following deep sequencing. SynDesign is expected to facilitate future research using SGE to investigate genes or variants of interest associated with human diseases. SynDesign is freely available at <ext-link xlink:href="https://deepcrispr.info/SynDesign" ext-link-type="uri">https://deepcrispr.info/SynDesign</ext-link> without a login process.</p>
    </abstract>
    <abstract abstract-type="graphical">
      <title>Graphical Abstract</title>
      <p>
        <fig position="float" id="ga1">
          <label>Graphical Abstract</label>
          <graphic xlink:href="gkae304figgra1" position="float"/>
        </fig>
      </p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Research Foundation of Korea</institution>
            <institution-id institution-id-type="DOI">10.13039/501100003725</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Korean government</institution>
          </institution-wrap>
        </funding-source>
        <award-id>2022R1A3B1078084</award-id>
        <award-id>2018R1A5A2025079</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Bio and Medical Technology Development Program of the NRF</institution>
          </institution-wrap>
        </funding-source>
        <award-id>2022M3A9E4017127</award-id>
        <award-id>2022M3A9F3017506</award-id>
        <award-id>RS-2023-00260968</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Yonsei Signature Research Cluster Program of 2023-22- 0012</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Brain Korea 21 FOUR Project for Medical Science</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>SNUH Kun-hee Lee Child Cancer and Rare Disease Project, Republic of Korea</institution>
          </institution-wrap>
        </funding-source>
        <award-id>22B-000-0101</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Lee Youn Jae</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="5"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>Introduction</title>
    <p>When first introduced, prime editing presented a novel and powerful utility to genome editing by introducing prime editing guide RNAs (pegRNAs) that could be designed to install all possible point mutations a well as small insertions and deletions (indels), or any combinations of these DNA alterations to a target DNA sequence (<xref rid="B1" ref-type="bibr">1</xref>). However, the design and evaluation of pegRNAs for efficient prime editing have been a challenge as various sequence and biochemical factors can attribute to efficient pegRNAs (<xref rid="B1" ref-type="bibr">1–3</xref>). Furthermore, cell conditions exhibiting differential levels of mismatch repair (MMR) systems can also play a role in determining editing efficiencies. Notably, introducing a synonymous mutation adjacent to the intended edit on the target DNA have been shown to improve on-target prime editing efficiency by diffusing the local cellular MMR activity (<xref rid="B3" ref-type="bibr">3</xref>). Additionally, the synonymous mutation can serve as an indicator of properly edited targets following deep sequencing (<xref rid="B4" ref-type="bibr">4</xref>). Taken together, the application of prime editing for saturation genome editing (SGE) can be a powerful tool in conducting systematic functional screening of variants for target genes of interest, especially for investigating variants of uncertain significance (VUS) that represent a major portion of the single nucleotide variants (SNVs) on the ClinVar and COSMIC databases, 95% and 99%, respectively (Figure <xref rid="F1" ref-type="fig">1</xref>). However, the designing and evaluation efficient pegRNAs for generating SNVs at every nucleotide position within a given coding sequence of a target gene present technical challenges that may hinder its wider application in research. Despite recent computational models based on deep learning greatly aiding our understanding of pegRNA designs and facilitating prime editing applications in diverse cell types and PEs (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>), reliable and easy-to-use tools for SGE library design and evaluation have been limited.</p>
    <fig position="float" id="F1">
      <label>Figure 1.</label>
      <caption>
        <p>Distribution of VUSs in ClinVar and COSMIC databases. Of the variants categorized as uncertain significance or unknow origin, ClinVar and COSMIC databases respectively (VUS or simplicity), a major portion of them are single nucleotide variants and easily targetable by SynDesign. Investigating these VUSs remains an important task for understanding their role in human disease.</p>
      </caption>
      <graphic xlink:href="gkae304fig1" position="float"/>
    </fig>
    <p>Here, we present SynDesign, a web-based platform developed for the systematic design and assessment of pegRNAs, specifically tailored for the construction of precision pegRNA libraries employed in SGE. SynDesign provides an efficient and user-friendly means to easily target genes or variants of interest, streamlining the automation of pegRNA design and evaluation processes. Moreover, it seamlessly incorporates synonymous mutation markers into pegRNA designs, generating a curated list of top-performing pegRNAs for experimental applications. SynDesign is expected to alleviate the labor-intensive procedures associated with pegRNA design and facilitate the widespread adoption of SGE across diverse research applications.</p>
  </sec>
  <sec sec-type="materials|methods" id="SEC2">
    <title>Materials and methods</title>
    <sec id="SEC2-1">
      <title>SynDesign webtool</title>
      <p>SynDesign was developed using Python 3.9.13 on CodeIgniter 5 based on PHP 5.2.4. The web interface was developed using Bootstrap 5 and made accessible using Apache 2.4.18.</p>
    </sec>
    <sec id="SEC2-2">
      <title>Input processing</title>
      <p>To facilitate the systematic targeting of genes or variants of interest, the major databases for obtaining reference gene information on the human genome and genetic variants were collected, cleaned and indexed for fast and resource-efficient manipulation. Databases included the NCBI’s RefSeq gene information (<xref rid="B7" ref-type="bibr">7</xref>), Ensembl database for vertebrate genomes (<xref rid="B8" ref-type="bibr">8</xref>), the HUGO Gene Nomenclature Committee, HGNC, database (<xref rid="B9" ref-type="bibr">9</xref>), where the gene name and symbol, with corresponding identification and accession numbers for representative gene forms were cross-referenced and verified using an in-house Python script. In doing so, a reliable reference list of &gt;18 000 human genes and their collective IDs from each database was established. In addition, we collected and indexed the latest version of ClinVar (<xref rid="B10" ref-type="bibr">10</xref>) and COSMIC (<xref rid="B11" ref-type="bibr">11</xref>) variant archives for quickly identifying variant ID queries and generating a library of pegRNAs targeting the variant location for installing or editing the mutation.</p>
    </sec>
    <sec id="SEC2-3">
      <title>PegRNA design and scoring</title>
      <p>Genic information for target genes including transcription start and end positions, the coding sequence (CDS) start and end positions, and the exon count are retrieved using the in-house reference gene list. Using these coordinates, the CDS sequences are fetched from genome version GRCh38/hg38. Within the given CDS sequence, all possible pegRNA designs are determined for each position in the CDS sequence to elicit all three SNV alterations. Components such as the reverse transcription template (RTT) (max 40 bp) and primer-binding site (PBS) (max 17 bp) sequences are determined according to DeepPrime input parameters. Variant inputs from the ClinVar and COSMIC archives or single position input require considerably less computational resources as only a single position is targeted.</p>
      <p>All pegRNAs are evaluated using DeepPrime and DeepPrime-FT and ranked according to predicted efficiency scores. DeepPrime and DeepPrime-FT are CNN + GRU-based deep learning model developed on pytorch 1.9.1 that predicts prime editing efficiencies for introducing 1–3-bp substitutions, insertions, or deletions at any given target sites in the human genome (<xref rid="B2" ref-type="bibr">2</xref>). It was developed and fine-tuned using more than 300 000 pegRNAs for a diverse group of prime editors and cell types and validated against multiple independent datasets from previous studies (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>).</p>
    </sec>
    <sec id="SEC2-4">
      <title>Output processing and visualization</title>
      <p>As co-editing of the PAM sequence has been shown to increase editing efficiency (<xref rid="B5" ref-type="bibr">5</xref>), the incorporation of a synonymous mutation marker is prioritized to the PAM sequence but can be user-specified to other region of the pegRNA design. Visualization of the results include important features of the top pegRNAs ranked according to the predicted efficiency scores included genic coordinates, nucleotide and amino acid changes, and <italic toggle="yes">Z</italic>-score graph of the top pegRNA designs against those from model testing for the corresponding PE and cell type (Figure <xref rid="F2" ref-type="fig">2</xref>). This contextual information provides a more complete understanding of their efficiency in relation to a more general performance of pegRNAs under similar experimental conditions.</p>
      <fig position="float" id="F2">
        <label>Figure 2.</label>
        <caption>
          <p>Sample Result Page from SynDesign. Interactive results page from <italic toggle="yes">TP53</italic> exon 5 run shows pertinent information regarding the pegRNAs ranked according to predicted efficiency scores from DeepPrime. The <italic toggle="yes">z</italic>-score plot depicts the score of the selected pegRNA compared to those from model training under the same prime editor and cellular conditions. Top 200 pegRNAs are shown as default but a link to download the full results is available at the bottom of the page.</p>
        </caption>
        <graphic xlink:href="gkae304fig2" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec sec-type="results" id="SEC3">
    <title>Results</title>
    <sec id="SEC3-1">
      <title>Analysis: gene target</title>
      <p>For GeneSym, NMID, Ensembl and HGNC, the target gene information is automatically filled within a dropdown menu that includes the corresponding target gene's gene symbol, chromosome number and strand, and the exon numbers that include the CDS for quick reference by the user. Exons can be targeted by the number with single exon being the best for current available resources. Recently, we used SynDesign to develop a saturation resistance profiling library of the <italic toggle="yes">EGFR</italic> gene against various the chemotherapy drugs, afatinib and osimertinib. A SGE library was designed and evaluated to profile over 2476 SNVs in the EGFR gene that included 95% (1726/1817) of the possible protein variants in the tyrosine kinase domain (exons 18–21) which represents an important functional hotspot for cancer-related mutations (<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B14" ref-type="bibr">14</xref>). SynDesign was able to compile a list of all feasible pegRNAs targeting every position in the <italic toggle="yes">EGFR</italic> gene to systematically evaluate this important oncogene. SynDesign determines the top pegRNAs for each position according to our DeepPrime/DeepPrime-FT prediction models and automatically incorporates a synonymous mutation marker that further enhances pegRNA efficiency and sequenced product identification.</p>
    </sec>
    <sec id="SEC3-2">
      <title>Analysis: variant targets</title>
      <p>For specific variant targets from ClinVar or COSMIC archives, the mutation ID from each database can be used without the lettering prefix fillers, VCV- and COSM-, respectively. The model or therapy setting switches the wild-type (unedited) and edited sequences in the input processing step to construct a library for disease modelling (installing the mutation) or disease therapy (correcting the mutation), respectively. There are more than 600K and 750K variants that are categorized as VUS on the ClinVar and COSMIC databases respectively. Of these VUSs, 95% and 99% are SNVs (Figure <xref rid="F1" ref-type="fig">1</xref>). SynDesign can quickly retrieve these VUSs to generate all possible pegRNA designs targeting the VUS and score each pegRNA using DeepPrime/DeepPrime-FT. This secondary function to SGE that retrieves target variants directly from the ClinVar and COSMIC archives can further enhance the systematic survey of VUSs associated with human disease such as cancers. SynDesign is expected to serve as a useful platform that can aid in addressing this critical need in the investigation of VUSs.</p>
    </sec>
    <sec id="SEC3-3">
      <title>Limitations of SynDesign</title>
      <p>The basic sequence and position inputs are intended for quick test runs as they do not involve gene annotation or additional annotation using the variant archives. The sequence input tests single unedited and edited sequences of 121-bp in length that follows the DeepPrime protocol, <ext-link xlink:href="https://deepcrispr.info/DeepPrime" ext-link-type="uri">https://deepcrispr.info/DeepPrime</ext-link>. The computational requirements for conducting full gene or multiple exon runs have proven to be prohibitive, surpassing reasonable runtimes and exceeding the VRAM limits of our existing webserver infrastructure.</p>
    </sec>
  </sec>
  <sec sec-type="discussion" id="SEC4">
    <title>Discussion</title>
    <p>This paper introduces a user-friendly platform designed for precision targeting of genes or variants of interest. The platform seamlessly integrates systematic pegRNA design with robust prediction models, DeepPrime and DeepPrime-FT. SynDesign generates results that include synonymous mutation markers and important features for the top predicted pegRNAs, facilitating precision SGE for target genes and constructing robust pegRNA libraries for variants of interest. Thorough documentation including all available parameters and sample inputs and expected interactive outcomes, are accessible through the Support section of the webpage.</p>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>Acknowledgements</title>
    <p>We would like to thank Younghye Kim and Seonmi Park for assisting with the experiments..</p>
  </ack>
  <sec sec-type="data-availability" id="SEC5">
    <title>Data availability</title>
    <p>SynDesign is freely available at <ext-link xlink:href="https://deepcrispr.info/SynDesign" ext-link-type="uri">https://deepcrispr.info/SynDesign</ext-link>. Webtool version of the custom Python code for guide design and feature extraction is available on <ext-link xlink:href="https://github.com/josephjinpark/SynDesign" ext-link-type="uri">https://github.com/josephjinpark/SynDesign</ext-link> and <ext-link xlink:href="https://doi.org/10.6084/m9.figshare.25565994" ext-link-type="uri">https://doi.org/10.6084/m9.figshare.25565994</ext-link>.</p>
  </sec>
  <sec id="SEC6">
    <title>Funding</title>
    <p>National Research Foundation of Korea grant funded by the Korean government (MSIT) [2022R1A3B1078084 to H.H.K., 2018R1A5A2025079 to H.H.K.]; Bio and Medical Technology Development Program of the NRF funded by the Korean government (MSIT) [2022M3A9E4017127 to H.H.K., 2022M3A9F3017506 to H.H.K., RS-2023-00260968 to H.H.K.]; Yonsei Signature Research Cluster Program of 2023-22- 0012 (to H.H.K.); Brain Korea 21 FOUR Project for Medical Science (Yonsei University College of Medicine); SNUH Kun-hee Lee Child Cancer and Rare Disease Project, Republic of Korea [22B-000-0101 to H.H.K.]; Yonsei Fellow Program, funded by Lee Youn Jae. Funding for open access charge: National Research Foundation of Korea grant funded by the Korean government (MSIT) [2022R1A3B1078084 to H.H.K., 2018R1A5A2025079 to H.H.K.]; Bio and Medical Technology Development Program of the NRF funded by the Korean government (MSIT) [2022M3A9E4017127 to H.H.K., 2022M3A9F3017506 to H.H.K., RS-2023-00260968 to H.H.K.]; Yonsei Signature Research Cluster Program of 2023-22- 0012 (to H.H.K.); Brain Korea 21 FOUR Project for Medical Science (Yonsei University College of Medicine); SNUH Kun-hee Lee Child Cancer and Rare Disease Project, Republic of Korea [22B-000-0101 to H.H.K.]; Yonsei Fellow Program, funded by Lee Youn Jae.</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. Authors declare no conflicts of interest.</p>
  </sec>
  <ref-list id="REF1">
    <title>References</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Anzalone</surname>  <given-names>A.V.</given-names></string-name>, <string-name><surname>Randolph</surname>  <given-names>P.B.</given-names></string-name>, <string-name><surname>Davis</surname>  <given-names>J.R.</given-names></string-name>, <string-name><surname>Sousa</surname>  <given-names>A.A.</given-names></string-name>, <string-name><surname>Koblan</surname>  <given-names>L.W.</given-names></string-name>, <string-name><surname>Levy</surname>  <given-names>J.M.</given-names></string-name>, <string-name><surname>Chen</surname>  <given-names>P.J.</given-names></string-name>, <string-name><surname>Wilson</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Newby</surname>  <given-names>G.A.</given-names></string-name>, <string-name><surname>Raguram</surname>  <given-names>A.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Search-and-replace genome editing without double-strand breaks or donor DNA</article-title>. <source>Nature</source>. <year>2019</year>; <volume>576</volume>:<fpage>149</fpage>–<lpage>157</lpage>.<pub-id pub-id-type="pmid">31634902</pub-id>
</mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yu</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>H.K.</given-names></string-name>, <string-name><surname>Park</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Kwak</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Cheong</surname>  <given-names>Y.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>D.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>H.H</given-names></string-name></person-group>  <article-title>Prediction of efficiencies for diverse prime editing systems in multiple cell types</article-title>. <source>Cell</source>. <year>2023</year>; <volume>186</volume>:<fpage>2256</fpage>–<lpage>2272</lpage>.<pub-id pub-id-type="pmid">37119812</pub-id>
</mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname>  <given-names>P.J.</given-names></string-name>, <string-name><surname>Hussmann</surname>  <given-names>J.A.</given-names></string-name>, <string-name><surname>Yan</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Knipping</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Ravisankar</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Chen</surname>  <given-names>P.F.</given-names></string-name>, <string-name><surname>Chen</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Nelson</surname>  <given-names>J.W.</given-names></string-name>, <string-name><surname>Newby</surname>  <given-names>G.A.</given-names></string-name>, <string-name><surname>Sahin</surname>  <given-names>M.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Enhanced prime editing systems by manipulating cellular determinants of editing outcomes</article-title>. <source>Cell</source>. <year>2021</year>; <volume>184</volume>:<fpage>5635</fpage>–<lpage>5652</lpage>.<pub-id pub-id-type="pmid">34653350</pub-id>
</mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Kim</surname>  <given-names>Y.</given-names></string-name>, <string-name><surname>Oh</surname>  <given-names>H.-C.</given-names></string-name>, <string-name><surname>Lee</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>H.H.</given-names></string-name></person-group>  <article-title>Saturation resistance profiling of EGFR variants against tyrosine kinase inhibitors using prime editing</article-title>. <year>2023</year>; <comment>bioRxiv doi:</comment><comment>05 December 2023, preprint: not peer reviewed</comment><pub-id pub-id-type="doi">10.1101/2023.12.03.569825</pub-id>.</mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname>  <given-names>H.K.</given-names></string-name>, <string-name><surname>Yu</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Park</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Min</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Lee</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Yoon</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>H.H.</given-names></string-name></person-group>  <article-title>Predicting the efficiency of prime editing guide RNAs in human cells</article-title>. <source>Nat. Biotechnol.</source>  <year>2021</year>; <volume>39</volume>:<fpage>198</fpage>–<lpage>206</lpage>.<pub-id pub-id-type="pmid">32958957</pub-id>
</mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mathis</surname>  <given-names>N.</given-names></string-name>, <string-name><surname>Allam</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Kissling</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Marquart</surname>  <given-names>K.F.</given-names></string-name>, <string-name><surname>Schmidheini</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Solari</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Balazs</surname>  <given-names>Z.</given-names></string-name>, <string-name><surname>Krauthammer</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Schwank</surname>  <given-names>G.</given-names></string-name></person-group>  <article-title>Predicting prime editing efficiency and product purity by deep learning</article-title>. <source>Nat. Biotechnol.</source>  <year>2023</year>; <volume>41</volume>:<fpage>1151</fpage>–<lpage>1159</lpage>.<pub-id pub-id-type="pmid">36646933</pub-id>
</mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>O’Leary</surname>  <given-names>N.A.</given-names></string-name>, <string-name><surname>Wright</surname>  <given-names>M.W.</given-names></string-name>, <string-name><surname>Brister</surname>  <given-names>J.R.</given-names></string-name>, <string-name><surname>Ciufo</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Haddad</surname>  <given-names>D.</given-names></string-name>, <string-name><surname>McVeigh</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Rajput</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Robbertse</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Smith-White</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Ako-Adjei</surname>  <given-names>D.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation</article-title>. <source>Nucleic Acids Res.</source>  <year>2016</year>; <volume>44</volume>:<fpage>D733</fpage>–<lpage>D745</lpage>.<pub-id pub-id-type="pmid">26553804</pub-id>
</mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Harrison</surname>  <given-names>P.W.</given-names></string-name>, <string-name><surname>Amode</surname>  <given-names>M.R.</given-names></string-name>, <string-name><surname>Austine-Orimoloye</surname>  <given-names>O.</given-names></string-name>, <string-name><surname>Azov</surname>  <given-names>A.G.</given-names></string-name>, <string-name><surname>Barba</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Barnes</surname>  <given-names>I.</given-names></string-name>, <string-name><surname>Becker</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Bennett</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Berry</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Bhai</surname>  <given-names>J.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Ensembl 2024</article-title>. <source>Nucleic Acids Res.</source>  <year>2024</year>; <volume>52</volume>:<fpage>D891</fpage>–<lpage>D899</lpage>.<pub-id pub-id-type="pmid">37953337</pub-id>
</mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Seal</surname>  <given-names>R.L.</given-names></string-name>, <string-name><surname>Braschi</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Gray</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Jones</surname>  <given-names>T.E.M.</given-names></string-name>, <string-name><surname>Tweedie</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Haim-Vilmovsky</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Bruford</surname>  <given-names>E.A.</given-names></string-name></person-group>  <article-title>Genenames.org: the HGNC resources in 2023</article-title>. <source>Nucleic Acids Res.</source>  <year>2023</year>; <volume>51</volume>:<fpage>D1003</fpage>–<lpage>D1009</lpage>.<pub-id pub-id-type="pmid">36243972</pub-id>
</mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Landrum</surname>  <given-names>M.J.</given-names></string-name>, <string-name><surname>Lee</surname>  <given-names>J.M.</given-names></string-name>, <string-name><surname>Benson</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Brown</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Chao</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Chitipiralla</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Gu</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Hart</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Hoffman</surname>  <given-names>D.</given-names></string-name>, <string-name><surname>Hoover</surname>  <given-names>J.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>ClinVar: public archive of interpretations of clinically relevant variants</article-title>. <source>Nucleic Acids Res.</source>  <year>2016</year>; <volume>44</volume>:<fpage>D862</fpage>–<lpage>D868</lpage>.<pub-id pub-id-type="pmid">26582918</pub-id>
</mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sondka</surname>  <given-names>Z.</given-names></string-name>, <string-name><surname>Dhir</surname>  <given-names>N.B.</given-names></string-name>, <string-name><surname>Carvalho-Silva</surname>  <given-names>D.</given-names></string-name>, <string-name><surname>Jupe</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Madhumita</surname></string-name>, <string-name><surname>McLaren</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Starkey</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Ward</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Wilding</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Ahmed</surname>  <given-names>M.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>COSMIC: a curated database of somatic variants and clinical data for cancer</article-title>. <source>Nucleic Acids Res.</source>  <year>2024</year>; <volume>52</volume>:<fpage>D1210</fpage>–<lpage>D1217</lpage>.<pub-id pub-id-type="pmid">38183204</pub-id>
</mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jang</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Jo</surname>  <given-names>D.H.</given-names></string-name>, <string-name><surname>Cho</surname>  <given-names>C.S.</given-names></string-name>, <string-name><surname>Shin</surname>  <given-names>J.H.</given-names></string-name>, <string-name><surname>Seo</surname>  <given-names>J.H.</given-names></string-name>, <string-name><surname>Yu</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Gopalappa</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>D.</given-names></string-name>, <string-name><surname>Cho</surname>  <given-names>S.R.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>J.H.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases</article-title>. <source>Nat. Biomed. Eng.</source>  <year>2022</year>; <volume>6</volume>:<fpage>181</fpage>–<lpage>194</lpage>.<pub-id pub-id-type="pmid">34446856</pub-id>
</mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Erwood</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Bily</surname>  <given-names>T.M.I.</given-names></string-name>, <string-name><surname>Lequyer</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Yan</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Gulati</surname>  <given-names>N.</given-names></string-name>, <string-name><surname>Brewer</surname>  <given-names>R.A.</given-names></string-name>, <string-name><surname>Zhou</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Pelletier</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Ivakine</surname>  <given-names>E.A.</given-names></string-name>, <string-name><surname>Cohn</surname>  <given-names>R.D.</given-names></string-name></person-group>  <article-title>Saturation variant interpretation using CRISPR prime editing</article-title>. <source>Nat. Biotechnol.</source>  <year>2022</year>; <volume>40</volume>:<fpage>885</fpage>–<lpage>895</lpage>.<pub-id pub-id-type="pmid">35190686</pub-id>
</mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sharma</surname>  <given-names>S.V.</given-names></string-name>, <string-name><surname>Bell</surname>  <given-names>D.W.</given-names></string-name>, <string-name><surname>Settleman</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Haber</surname>  <given-names>D.A.</given-names></string-name></person-group>  <article-title>Epidermal growth factor receptor mutations in lung cancer</article-title>. <source>Nat. Rev. Cancer</source>. <year>2007</year>; <volume>7</volume>:<fpage>169</fpage>–<lpage>181</lpage>.<pub-id pub-id-type="pmid">17318210</pub-id>
</mixed-citation>
    </ref>
  </ref-list>
</back>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">11223855</article-id>
    <article-id pub-id-type="pmid">38682594</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkae304</article-id>
    <article-id pub-id-type="publisher-id">gkae304</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00010</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Web Server Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>SynDesign: web-based prime editing guide RNA design and evaluation tool for saturation genome editing</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Park</surname>
          <given-names>Jinman</given-names>
        </name>
        <aff><institution>Department of Pharmacology, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Graduate School of Medical Science, Brain Korea 21 Plus Project for Medical Sciences, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yu</surname>
          <given-names>Goosang</given-names>
        </name>
        <aff><institution>Department of Pharmacology, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Graduate School of Medical Science, Brain Korea 21 Plus Project for Medical Sciences, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Seo</surname>
          <given-names>Sang-Yeon</given-names>
        </name>
        <aff><institution>Department of Pharmacology, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Graduate School of Medical Science, Brain Korea 21 Plus Project for Medical Sciences, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yang</surname>
          <given-names>Jinyeong</given-names>
        </name>
        <aff><institution>Department of Pharmacology, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Graduate School of Medical Science, Brain Korea 21 Plus Project for Medical Sciences, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4693-738X</contrib-id>
        <name>
          <surname>Kim</surname>
          <given-names>Hyongbum Henry</given-names>
        </name>
        <!--hkim1@yuhs.ac-->
        <aff><institution>Department of Pharmacology, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Graduate School of Medical Science, Brain Korea 21 Plus Project for Medical Sciences, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Severance Biomedical Science Institute, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Center for Nanomedicine, Institute for Basic Science (IBS)</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Yonsei-IBS Institute, Yonsei University</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine</institution>, Seoul <addr-line>03722</addr-line>, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Woo Choo Lee Institute for Precision Drug Development, Yonsei University College of Medicine</institution>, Seoul 03722, <country country="KR">Republic of Korea</country></aff>
        <aff><institution>Won-Sang Lee Institute for Hearing Loss, Yonsei University College of Medicine</institution>, Seoul 03722, <country country="KR">Republic of Korea</country></aff>
        <xref rid="COR1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +82 2 2228 0879; Fax: +82 2 313 1894; Email: <email>hkim1@yuhs.ac</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <day>05</day>
      <month>7</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2024-04-29">
      <day>29</day>
      <month>4</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>29</day>
      <month>4</month>
      <year>2024</year>
    </pub-date>
    <volume>52</volume>
    <issue>W1</issue>
    <fpage>W121</fpage>
    <lpage>W125</lpage>
    <history>
      <date date-type="accepted">
        <day>24</day>
        <month>4</month>
        <year>2024</year>
      </date>
      <date date-type="rev-recd">
        <day>22</day>
        <month>3</month>
        <year>2024</year>
      </date>
      <date date-type="received">
        <day>04</day>
        <month>2</month>
        <year>2024</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2024. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2024</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkae304.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Saturation genome editing (SGE) enables in-depth functional evaluation of disease-associated genes and variants by generating all possible single nucleotide variants (SNVs) within a given coding region. Although prime editing can be employed for inducing these SNVs, designing efficient prime editing guide RNAs (pegRNAs) can be challenging and time-consuming. Here, we present SynDesign, an easy-to-use webtool for the design, evaluation, and construction precision pegRNA libraries for SGE with synonymous mutation markers. SynDesign offers a simple yet powerful interface that automates the generation of all feasible pegRNA designs for a target gene or variant of interest. The pegRNAs are selected using the state-of-the-art models to predict prime editing efficiencies for various prime editors and cell types. Top-scoring pegRNA designs are further enhanced using synonymous mutation markers which improve pegRNA efficiency by diffusing the cellular mismatch repair mechanism and serve as sequence markers for improved identification of intended edits following deep sequencing. SynDesign is expected to facilitate future research using SGE to investigate genes or variants of interest associated with human diseases. SynDesign is freely available at <ext-link xlink:href="https://deepcrispr.info/SynDesign" ext-link-type="uri">https://deepcrispr.info/SynDesign</ext-link> without a login process.</p>
    </abstract>
    <abstract abstract-type="graphical">
      <title>Graphical Abstract</title>
      <p>
        <fig position="float" id="ga1">
          <label>Graphical Abstract</label>
          <graphic xlink:href="gkae304figgra1" position="float"/>
        </fig>
      </p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Research Foundation of Korea</institution>
            <institution-id institution-id-type="DOI">10.13039/501100003725</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Korean government</institution>
          </institution-wrap>
        </funding-source>
        <award-id>2022R1A3B1078084</award-id>
        <award-id>2018R1A5A2025079</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Bio and Medical Technology Development Program of the NRF</institution>
          </institution-wrap>
        </funding-source>
        <award-id>2022M3A9E4017127</award-id>
        <award-id>2022M3A9F3017506</award-id>
        <award-id>RS-2023-00260968</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Yonsei Signature Research Cluster Program of 2023-22- 0012</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Brain Korea 21 FOUR Project for Medical Science</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>SNUH Kun-hee Lee Child Cancer and Rare Disease Project, Republic of Korea</institution>
          </institution-wrap>
        </funding-source>
        <award-id>22B-000-0101</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>Lee Youn Jae</institution>
          </institution-wrap>
        </funding-source>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="5"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>Introduction</title>
    <p>When first introduced, prime editing presented a novel and powerful utility to genome editing by introducing prime editing guide RNAs (pegRNAs) that could be designed to install all possible point mutations a well as small insertions and deletions (indels), or any combinations of these DNA alterations to a target DNA sequence (<xref rid="B1" ref-type="bibr">1</xref>). However, the design and evaluation of pegRNAs for efficient prime editing have been a challenge as various sequence and biochemical factors can attribute to efficient pegRNAs (<xref rid="B1" ref-type="bibr">1–3</xref>). Furthermore, cell conditions exhibiting differential levels of mismatch repair (MMR) systems can also play a role in determining editing efficiencies. Notably, introducing a synonymous mutation adjacent to the intended edit on the target DNA have been shown to improve on-target prime editing efficiency by diffusing the local cellular MMR activity (<xref rid="B3" ref-type="bibr">3</xref>). Additionally, the synonymous mutation can serve as an indicator of properly edited targets following deep sequencing (<xref rid="B4" ref-type="bibr">4</xref>). Taken together, the application of prime editing for saturation genome editing (SGE) can be a powerful tool in conducting systematic functional screening of variants for target genes of interest, especially for investigating variants of uncertain significance (VUS) that represent a major portion of the single nucleotide variants (SNVs) on the ClinVar and COSMIC databases, 95% and 99%, respectively (Figure <xref rid="F1" ref-type="fig">1</xref>). However, the designing and evaluation efficient pegRNAs for generating SNVs at every nucleotide position within a given coding sequence of a target gene present technical challenges that may hinder its wider application in research. Despite recent computational models based on deep learning greatly aiding our understanding of pegRNA designs and facilitating prime editing applications in diverse cell types and PEs (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>), reliable and easy-to-use tools for SGE library design and evaluation have been limited.</p>
    <fig position="float" id="F1">
      <label>Figure 1.</label>
      <caption>
        <p>Distribution of VUSs in ClinVar and COSMIC databases. Of the variants categorized as uncertain significance or unknow origin, ClinVar and COSMIC databases respectively (VUS or simplicity), a major portion of them are single nucleotide variants and easily targetable by SynDesign. Investigating these VUSs remains an important task for understanding their role in human disease.</p>
      </caption>
      <graphic xlink:href="gkae304fig1" position="float"/>
    </fig>
    <p>Here, we present SynDesign, a web-based platform developed for the systematic design and assessment of pegRNAs, specifically tailored for the construction of precision pegRNA libraries employed in SGE. SynDesign provides an efficient and user-friendly means to easily target genes or variants of interest, streamlining the automation of pegRNA design and evaluation processes. Moreover, it seamlessly incorporates synonymous mutation markers into pegRNA designs, generating a curated list of top-performing pegRNAs for experimental applications. SynDesign is expected to alleviate the labor-intensive procedures associated with pegRNA design and facilitate the widespread adoption of SGE across diverse research applications.</p>
  </sec>
  <sec sec-type="materials|methods" id="SEC2">
    <title>Materials and methods</title>
    <sec id="SEC2-1">
      <title>SynDesign webtool</title>
      <p>SynDesign was developed using Python 3.9.13 on CodeIgniter 5 based on PHP 5.2.4. The web interface was developed using Bootstrap 5 and made accessible using Apache 2.4.18.</p>
    </sec>
    <sec id="SEC2-2">
      <title>Input processing</title>
      <p>To facilitate the systematic targeting of genes or variants of interest, the major databases for obtaining reference gene information on the human genome and genetic variants were collected, cleaned and indexed for fast and resource-efficient manipulation. Databases included the NCBI’s RefSeq gene information (<xref rid="B7" ref-type="bibr">7</xref>), Ensembl database for vertebrate genomes (<xref rid="B8" ref-type="bibr">8</xref>), the HUGO Gene Nomenclature Committee, HGNC, database (<xref rid="B9" ref-type="bibr">9</xref>), where the gene name and symbol, with corresponding identification and accession numbers for representative gene forms were cross-referenced and verified using an in-house Python script. In doing so, a reliable reference list of &gt;18 000 human genes and their collective IDs from each database was established. In addition, we collected and indexed the latest version of ClinVar (<xref rid="B10" ref-type="bibr">10</xref>) and COSMIC (<xref rid="B11" ref-type="bibr">11</xref>) variant archives for quickly identifying variant ID queries and generating a library of pegRNAs targeting the variant location for installing or editing the mutation.</p>
    </sec>
    <sec id="SEC2-3">
      <title>PegRNA design and scoring</title>
      <p>Genic information for target genes including transcription start and end positions, the coding sequence (CDS) start and end positions, and the exon count are retrieved using the in-house reference gene list. Using these coordinates, the CDS sequences are fetched from genome version GRCh38/hg38. Within the given CDS sequence, all possible pegRNA designs are determined for each position in the CDS sequence to elicit all three SNV alterations. Components such as the reverse transcription template (RTT) (max 40 bp) and primer-binding site (PBS) (max 17 bp) sequences are determined according to DeepPrime input parameters. Variant inputs from the ClinVar and COSMIC archives or single position input require considerably less computational resources as only a single position is targeted.</p>
      <p>All pegRNAs are evaluated using DeepPrime and DeepPrime-FT and ranked according to predicted efficiency scores. DeepPrime and DeepPrime-FT are CNN + GRU-based deep learning model developed on pytorch 1.9.1 that predicts prime editing efficiencies for introducing 1–3-bp substitutions, insertions, or deletions at any given target sites in the human genome (<xref rid="B2" ref-type="bibr">2</xref>). It was developed and fine-tuned using more than 300 000 pegRNAs for a diverse group of prime editors and cell types and validated against multiple independent datasets from previous studies (<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>).</p>
    </sec>
    <sec id="SEC2-4">
      <title>Output processing and visualization</title>
      <p>As co-editing of the PAM sequence has been shown to increase editing efficiency (<xref rid="B5" ref-type="bibr">5</xref>), the incorporation of a synonymous mutation marker is prioritized to the PAM sequence but can be user-specified to other region of the pegRNA design. Visualization of the results include important features of the top pegRNAs ranked according to the predicted efficiency scores included genic coordinates, nucleotide and amino acid changes, and <italic toggle="yes">Z</italic>-score graph of the top pegRNA designs against those from model testing for the corresponding PE and cell type (Figure <xref rid="F2" ref-type="fig">2</xref>). This contextual information provides a more complete understanding of their efficiency in relation to a more general performance of pegRNAs under similar experimental conditions.</p>
      <fig position="float" id="F2">
        <label>Figure 2.</label>
        <caption>
          <p>Sample Result Page from SynDesign. Interactive results page from <italic toggle="yes">TP53</italic> exon 5 run shows pertinent information regarding the pegRNAs ranked according to predicted efficiency scores from DeepPrime. The <italic toggle="yes">z</italic>-score plot depicts the score of the selected pegRNA compared to those from model training under the same prime editor and cellular conditions. Top 200 pegRNAs are shown as default but a link to download the full results is available at the bottom of the page.</p>
        </caption>
        <graphic xlink:href="gkae304fig2" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec sec-type="results" id="SEC3">
    <title>Results</title>
    <sec id="SEC3-1">
      <title>Analysis: gene target</title>
      <p>For GeneSym, NMID, Ensembl and HGNC, the target gene information is automatically filled within a dropdown menu that includes the corresponding target gene's gene symbol, chromosome number and strand, and the exon numbers that include the CDS for quick reference by the user. Exons can be targeted by the number with single exon being the best for current available resources. Recently, we used SynDesign to develop a saturation resistance profiling library of the <italic toggle="yes">EGFR</italic> gene against various the chemotherapy drugs, afatinib and osimertinib. A SGE library was designed and evaluated to profile over 2476 SNVs in the EGFR gene that included 95% (1726/1817) of the possible protein variants in the tyrosine kinase domain (exons 18–21) which represents an important functional hotspot for cancer-related mutations (<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B14" ref-type="bibr">14</xref>). SynDesign was able to compile a list of all feasible pegRNAs targeting every position in the <italic toggle="yes">EGFR</italic> gene to systematically evaluate this important oncogene. SynDesign determines the top pegRNAs for each position according to our DeepPrime/DeepPrime-FT prediction models and automatically incorporates a synonymous mutation marker that further enhances pegRNA efficiency and sequenced product identification.</p>
    </sec>
    <sec id="SEC3-2">
      <title>Analysis: variant targets</title>
      <p>For specific variant targets from ClinVar or COSMIC archives, the mutation ID from each database can be used without the lettering prefix fillers, VCV- and COSM-, respectively. The model or therapy setting switches the wild-type (unedited) and edited sequences in the input processing step to construct a library for disease modelling (installing the mutation) or disease therapy (correcting the mutation), respectively. There are more than 600K and 750K variants that are categorized as VUS on the ClinVar and COSMIC databases respectively. Of these VUSs, 95% and 99% are SNVs (Figure <xref rid="F1" ref-type="fig">1</xref>). SynDesign can quickly retrieve these VUSs to generate all possible pegRNA designs targeting the VUS and score each pegRNA using DeepPrime/DeepPrime-FT. This secondary function to SGE that retrieves target variants directly from the ClinVar and COSMIC archives can further enhance the systematic survey of VUSs associated with human disease such as cancers. SynDesign is expected to serve as a useful platform that can aid in addressing this critical need in the investigation of VUSs.</p>
    </sec>
    <sec id="SEC3-3">
      <title>Limitations of SynDesign</title>
      <p>The basic sequence and position inputs are intended for quick test runs as they do not involve gene annotation or additional annotation using the variant archives. The sequence input tests single unedited and edited sequences of 121-bp in length that follows the DeepPrime protocol, <ext-link xlink:href="https://deepcrispr.info/DeepPrime" ext-link-type="uri">https://deepcrispr.info/DeepPrime</ext-link>. The computational requirements for conducting full gene or multiple exon runs have proven to be prohibitive, surpassing reasonable runtimes and exceeding the VRAM limits of our existing webserver infrastructure.</p>
    </sec>
  </sec>
  <sec sec-type="discussion" id="SEC4">
    <title>Discussion</title>
    <p>This paper introduces a user-friendly platform designed for precision targeting of genes or variants of interest. The platform seamlessly integrates systematic pegRNA design with robust prediction models, DeepPrime and DeepPrime-FT. SynDesign generates results that include synonymous mutation markers and important features for the top predicted pegRNAs, facilitating precision SGE for target genes and constructing robust pegRNA libraries for variants of interest. Thorough documentation including all available parameters and sample inputs and expected interactive outcomes, are accessible through the Support section of the webpage.</p>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>Acknowledgements</title>
    <p>We would like to thank Younghye Kim and Seonmi Park for assisting with the experiments..</p>
  </ack>
  <sec sec-type="data-availability" id="SEC5">
    <title>Data availability</title>
    <p>SynDesign is freely available at <ext-link xlink:href="https://deepcrispr.info/SynDesign" ext-link-type="uri">https://deepcrispr.info/SynDesign</ext-link>. Webtool version of the custom Python code for guide design and feature extraction is available on <ext-link xlink:href="https://github.com/josephjinpark/SynDesign" ext-link-type="uri">https://github.com/josephjinpark/SynDesign</ext-link> and <ext-link xlink:href="https://doi.org/10.6084/m9.figshare.25565994" ext-link-type="uri">https://doi.org/10.6084/m9.figshare.25565994</ext-link>.</p>
  </sec>
  <sec id="SEC6">
    <title>Funding</title>
    <p>National Research Foundation of Korea grant funded by the Korean government (MSIT) [2022R1A3B1078084 to H.H.K., 2018R1A5A2025079 to H.H.K.]; Bio and Medical Technology Development Program of the NRF funded by the Korean government (MSIT) [2022M3A9E4017127 to H.H.K., 2022M3A9F3017506 to H.H.K., RS-2023-00260968 to H.H.K.]; Yonsei Signature Research Cluster Program of 2023-22- 0012 (to H.H.K.); Brain Korea 21 FOUR Project for Medical Science (Yonsei University College of Medicine); SNUH Kun-hee Lee Child Cancer and Rare Disease Project, Republic of Korea [22B-000-0101 to H.H.K.]; Yonsei Fellow Program, funded by Lee Youn Jae. Funding for open access charge: National Research Foundation of Korea grant funded by the Korean government (MSIT) [2022R1A3B1078084 to H.H.K., 2018R1A5A2025079 to H.H.K.]; Bio and Medical Technology Development Program of the NRF funded by the Korean government (MSIT) [2022M3A9E4017127 to H.H.K., 2022M3A9F3017506 to H.H.K., RS-2023-00260968 to H.H.K.]; Yonsei Signature Research Cluster Program of 2023-22- 0012 (to H.H.K.); Brain Korea 21 FOUR Project for Medical Science (Yonsei University College of Medicine); SNUH Kun-hee Lee Child Cancer and Rare Disease Project, Republic of Korea [22B-000-0101 to H.H.K.]; Yonsei Fellow Program, funded by Lee Youn Jae.</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. Authors declare no conflicts of interest.</p>
  </sec>
  <ref-list id="REF1">
    <title>References</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Anzalone</surname>  <given-names>A.V.</given-names></string-name>, <string-name><surname>Randolph</surname>  <given-names>P.B.</given-names></string-name>, <string-name><surname>Davis</surname>  <given-names>J.R.</given-names></string-name>, <string-name><surname>Sousa</surname>  <given-names>A.A.</given-names></string-name>, <string-name><surname>Koblan</surname>  <given-names>L.W.</given-names></string-name>, <string-name><surname>Levy</surname>  <given-names>J.M.</given-names></string-name>, <string-name><surname>Chen</surname>  <given-names>P.J.</given-names></string-name>, <string-name><surname>Wilson</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Newby</surname>  <given-names>G.A.</given-names></string-name>, <string-name><surname>Raguram</surname>  <given-names>A.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Search-and-replace genome editing without double-strand breaks or donor DNA</article-title>. <source>Nature</source>. <year>2019</year>; <volume>576</volume>:<fpage>149</fpage>–<lpage>157</lpage>.<pub-id pub-id-type="pmid">31634902</pub-id>
</mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yu</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>H.K.</given-names></string-name>, <string-name><surname>Park</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Kwak</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Cheong</surname>  <given-names>Y.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>D.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>H.H</given-names></string-name></person-group>  <article-title>Prediction of efficiencies for diverse prime editing systems in multiple cell types</article-title>. <source>Cell</source>. <year>2023</year>; <volume>186</volume>:<fpage>2256</fpage>–<lpage>2272</lpage>.<pub-id pub-id-type="pmid">37119812</pub-id>
</mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname>  <given-names>P.J.</given-names></string-name>, <string-name><surname>Hussmann</surname>  <given-names>J.A.</given-names></string-name>, <string-name><surname>Yan</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Knipping</surname>  <given-names>F.</given-names></string-name>, <string-name><surname>Ravisankar</surname>  <given-names>P.</given-names></string-name>, <string-name><surname>Chen</surname>  <given-names>P.F.</given-names></string-name>, <string-name><surname>Chen</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Nelson</surname>  <given-names>J.W.</given-names></string-name>, <string-name><surname>Newby</surname>  <given-names>G.A.</given-names></string-name>, <string-name><surname>Sahin</surname>  <given-names>M.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Enhanced prime editing systems by manipulating cellular determinants of editing outcomes</article-title>. <source>Cell</source>. <year>2021</year>; <volume>184</volume>:<fpage>5635</fpage>–<lpage>5652</lpage>.<pub-id pub-id-type="pmid">34653350</pub-id>
</mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Kim</surname>  <given-names>Y.</given-names></string-name>, <string-name><surname>Oh</surname>  <given-names>H.-C.</given-names></string-name>, <string-name><surname>Lee</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>H.H.</given-names></string-name></person-group>  <article-title>Saturation resistance profiling of EGFR variants against tyrosine kinase inhibitors using prime editing</article-title>. <year>2023</year>; <comment>bioRxiv doi:</comment><comment>05 December 2023, preprint: not peer reviewed</comment><pub-id pub-id-type="doi">10.1101/2023.12.03.569825</pub-id>.</mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname>  <given-names>H.K.</given-names></string-name>, <string-name><surname>Yu</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Park</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Min</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Lee</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Yoon</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>H.H.</given-names></string-name></person-group>  <article-title>Predicting the efficiency of prime editing guide RNAs in human cells</article-title>. <source>Nat. Biotechnol.</source>  <year>2021</year>; <volume>39</volume>:<fpage>198</fpage>–<lpage>206</lpage>.<pub-id pub-id-type="pmid">32958957</pub-id>
</mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mathis</surname>  <given-names>N.</given-names></string-name>, <string-name><surname>Allam</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Kissling</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Marquart</surname>  <given-names>K.F.</given-names></string-name>, <string-name><surname>Schmidheini</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Solari</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Balazs</surname>  <given-names>Z.</given-names></string-name>, <string-name><surname>Krauthammer</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Schwank</surname>  <given-names>G.</given-names></string-name></person-group>  <article-title>Predicting prime editing efficiency and product purity by deep learning</article-title>. <source>Nat. Biotechnol.</source>  <year>2023</year>; <volume>41</volume>:<fpage>1151</fpage>–<lpage>1159</lpage>.<pub-id pub-id-type="pmid">36646933</pub-id>
</mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>O’Leary</surname>  <given-names>N.A.</given-names></string-name>, <string-name><surname>Wright</surname>  <given-names>M.W.</given-names></string-name>, <string-name><surname>Brister</surname>  <given-names>J.R.</given-names></string-name>, <string-name><surname>Ciufo</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Haddad</surname>  <given-names>D.</given-names></string-name>, <string-name><surname>McVeigh</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Rajput</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Robbertse</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Smith-White</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Ako-Adjei</surname>  <given-names>D.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation</article-title>. <source>Nucleic Acids Res.</source>  <year>2016</year>; <volume>44</volume>:<fpage>D733</fpage>–<lpage>D745</lpage>.<pub-id pub-id-type="pmid">26553804</pub-id>
</mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Harrison</surname>  <given-names>P.W.</given-names></string-name>, <string-name><surname>Amode</surname>  <given-names>M.R.</given-names></string-name>, <string-name><surname>Austine-Orimoloye</surname>  <given-names>O.</given-names></string-name>, <string-name><surname>Azov</surname>  <given-names>A.G.</given-names></string-name>, <string-name><surname>Barba</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Barnes</surname>  <given-names>I.</given-names></string-name>, <string-name><surname>Becker</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Bennett</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Berry</surname>  <given-names>A.</given-names></string-name>, <string-name><surname>Bhai</surname>  <given-names>J.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Ensembl 2024</article-title>. <source>Nucleic Acids Res.</source>  <year>2024</year>; <volume>52</volume>:<fpage>D891</fpage>–<lpage>D899</lpage>.<pub-id pub-id-type="pmid">37953337</pub-id>
</mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Seal</surname>  <given-names>R.L.</given-names></string-name>, <string-name><surname>Braschi</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Gray</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Jones</surname>  <given-names>T.E.M.</given-names></string-name>, <string-name><surname>Tweedie</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Haim-Vilmovsky</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Bruford</surname>  <given-names>E.A.</given-names></string-name></person-group>  <article-title>Genenames.org: the HGNC resources in 2023</article-title>. <source>Nucleic Acids Res.</source>  <year>2023</year>; <volume>51</volume>:<fpage>D1003</fpage>–<lpage>D1009</lpage>.<pub-id pub-id-type="pmid">36243972</pub-id>
</mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Landrum</surname>  <given-names>M.J.</given-names></string-name>, <string-name><surname>Lee</surname>  <given-names>J.M.</given-names></string-name>, <string-name><surname>Benson</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Brown</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Chao</surname>  <given-names>C.</given-names></string-name>, <string-name><surname>Chitipiralla</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Gu</surname>  <given-names>B.</given-names></string-name>, <string-name><surname>Hart</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Hoffman</surname>  <given-names>D.</given-names></string-name>, <string-name><surname>Hoover</surname>  <given-names>J.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>ClinVar: public archive of interpretations of clinically relevant variants</article-title>. <source>Nucleic Acids Res.</source>  <year>2016</year>; <volume>44</volume>:<fpage>D862</fpage>–<lpage>D868</lpage>.<pub-id pub-id-type="pmid">26582918</pub-id>
</mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sondka</surname>  <given-names>Z.</given-names></string-name>, <string-name><surname>Dhir</surname>  <given-names>N.B.</given-names></string-name>, <string-name><surname>Carvalho-Silva</surname>  <given-names>D.</given-names></string-name>, <string-name><surname>Jupe</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Madhumita</surname></string-name>, <string-name><surname>McLaren</surname>  <given-names>K.</given-names></string-name>, <string-name><surname>Starkey</surname>  <given-names>M.</given-names></string-name>, <string-name><surname>Ward</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Wilding</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Ahmed</surname>  <given-names>M.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>COSMIC: a curated database of somatic variants and clinical data for cancer</article-title>. <source>Nucleic Acids Res.</source>  <year>2024</year>; <volume>52</volume>:<fpage>D1210</fpage>–<lpage>D1217</lpage>.<pub-id pub-id-type="pmid">38183204</pub-id>
</mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jang</surname>  <given-names>H.</given-names></string-name>, <string-name><surname>Jo</surname>  <given-names>D.H.</given-names></string-name>, <string-name><surname>Cho</surname>  <given-names>C.S.</given-names></string-name>, <string-name><surname>Shin</surname>  <given-names>J.H.</given-names></string-name>, <string-name><surname>Seo</surname>  <given-names>J.H.</given-names></string-name>, <string-name><surname>Yu</surname>  <given-names>G.</given-names></string-name>, <string-name><surname>Gopalappa</surname>  <given-names>R.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>D.</given-names></string-name>, <string-name><surname>Cho</surname>  <given-names>S.R.</given-names></string-name>, <string-name><surname>Kim</surname>  <given-names>J.H.</given-names></string-name>  <etal>et al</etal>.</person-group>  <article-title>Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases</article-title>. <source>Nat. Biomed. Eng.</source>  <year>2022</year>; <volume>6</volume>:<fpage>181</fpage>–<lpage>194</lpage>.<pub-id pub-id-type="pmid">34446856</pub-id>
</mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Erwood</surname>  <given-names>S.</given-names></string-name>, <string-name><surname>Bily</surname>  <given-names>T.M.I.</given-names></string-name>, <string-name><surname>Lequyer</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Yan</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Gulati</surname>  <given-names>N.</given-names></string-name>, <string-name><surname>Brewer</surname>  <given-names>R.A.</given-names></string-name>, <string-name><surname>Zhou</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Pelletier</surname>  <given-names>L.</given-names></string-name>, <string-name><surname>Ivakine</surname>  <given-names>E.A.</given-names></string-name>, <string-name><surname>Cohn</surname>  <given-names>R.D.</given-names></string-name></person-group>  <article-title>Saturation variant interpretation using CRISPR prime editing</article-title>. <source>Nat. Biotechnol.</source>  <year>2022</year>; <volume>40</volume>:<fpage>885</fpage>–<lpage>895</lpage>.<pub-id pub-id-type="pmid">35190686</pub-id>
</mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sharma</surname>  <given-names>S.V.</given-names></string-name>, <string-name><surname>Bell</surname>  <given-names>D.W.</given-names></string-name>, <string-name><surname>Settleman</surname>  <given-names>J.</given-names></string-name>, <string-name><surname>Haber</surname>  <given-names>D.A.</given-names></string-name></person-group>  <article-title>Epidermal growth factor receptor mutations in lung cancer</article-title>. <source>Nat. Rev. Cancer</source>. <year>2007</year>; <volume>7</volume>:<fpage>169</fpage>–<lpage>181</lpage>.<pub-id pub-id-type="pmid">17318210</pub-id>
</mixed-citation>
    </ref>
  </ref-list>
</back>
